Stockscreener 앱 받기
7.845
0.00%
0.005
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancor - TradingView
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billion - GuruFocus
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha
Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target - marketscreener.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc.RGLS - PR Newswire
India’s Competition Commission Clears J&K Bank in Antitrust Case - PYMNTS.com
Top Midday Gainers - marketscreener.com
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull
Novartis to buy Regulus Therapeutics for up to $1.7 billion - MSN
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters
Novartis to Acquire Regulus Therapeutics in Potential $1.7B Deal - Contract Pharma
Generac, Regulus Therapeutics, Garmin - TradingView
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
Regulus Therapeutics' stock price doubles on Novartis's buyout offer - TradingView
Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus
Latham & Watkins Advises Regulus Therapeutics in Acquisition by Novartis AG - Latham & Watkins LLP
Swiss pharma giant Novartis to acquire San Diego biotech Regulus in $1.7B deal - Axios
Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement - The Globe and Mail
Novartis to acquire Regulus Therapeutics for up to $1.7 billion - PharmaLive
Regulus Announces Merger Agreement with Novartis - TipRanks
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - The Joplin Globe
Regulus Therapeutics stock soars on acquisition deal with Novartis - Investing.com
Regulus Therapeutics Upon Termination Of Merger Deal Under Some Circumstances, Co To Pay Parent Termination Fee Of $27.3 Million - TradingView
Novartis (NVS) to Acquire Regulus Therapeutics for $0.8B - GuruFocus
Novartis (NVS) to Acquire Regulus Therapeutics in $0.8B Deal | N - GuruFocus
Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg.com
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Regulus Therapeutics Enters into Agreement to be Acquired by Nov - GuruFocus
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure - The Manila Times
Novartis to Acquire Regulus Therapeutics - marketscreener.com
Novartis to acquire Regulus for $7.00 a share in cash (RGLS:NASDAQ) - Seeking Alpha
Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG - marketscreener.com
Novartis to buy Regulus in deal worth up to $1.7B - breakingthenews.net
0.03%
0.49%
자본화:
|
볼륨(24시간):